These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36178566)

  • 41. Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease.
    Kastl AJ; Weaver KN; Zhang X; Strople JA; Adler J; Dubinsky MC; Bousvaros A; Watkins R; Dai X; Chen W; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda EA; Farraye FA; Chun KY; Zikry M; Fernando M; Bastidas M; Hernandez CG; Craig RG; Boccieri ME; Firestine A; Long MD; Kappelman MD
    Am J Gastroenterol; 2023 Jan; 118(1):129-137. PubMed ID: 36114773
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
    Maruyama A; Sawa T; Teramukai S; Katoh N
    J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
    EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Surveillance of Side Effects after Two Doses of COVID-19 Vaccines among Patients with Comorbid Conditions: A Sub-Cohort Analysis from Saudi Arabia.
    Mallhi TH; Khan YH; Butt MH; Salman M; Tanveer N; Alotaibi NH; Alzarea AI; Alanazi AS
    Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557002
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence and Drivers of COVID-19 Vaccine Booster Hesitancy Among German University Students and Employees.
    Attia S; Mausbach K; Klugar M; Howaldt HP; Riad A
    Front Public Health; 2022; 10():846861. PubMed ID: 35462827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study.
    Kian W; Zemel M; Kestenbaum EH; Rouvinov K; Alguayn W; Levitas D; Ievko A; Michlin R; Abod MA; Massalha I; Chernomordikov E; Sharb AA; Shalata W; Levison E; Roisman LC; Lavrenkov K; Peled N; Nesher L; Yakobson A
    Medicine (Baltimore); 2022 Jan; 101(2):e28561. PubMed ID: 35029223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. COVID-19 vaccine hesitancy and vaccine passports: a cross-sectional conjoint experiment in Japan.
    Okamoto S; Kamimura K; Komamura K
    BMJ Open; 2022 Jun; 12(6):e060829. PubMed ID: 35710243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California.
    Andrejko KL; Pry J; Myers JF; Jewell NP; Openshaw J; Watt J; Jain S; Lewnard JA;
    Clin Infect Dis; 2022 Apr; 74(8):1382-1389. PubMed ID: 34282839
    [TBL] [Abstract][Full Text] [Related]  

  • 49. COVID-19 Vaccine Hesitancy in Patients with Inflammatory Bowel Disease.
    Clarke K; Pelton M; Stuart A; Tinsley A; Dalessio S; Bernasko N; Williams ED; Coates M
    Dig Dis Sci; 2022 Oct; 67(10):4671-4677. PubMed ID: 35092534
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα.
    Edelman-Klapper H; Zittan E; Bar-Gil Shitrit A; Rabinowitz KM; Goren I; Avni-Biron I; Ollech JE; Lichtenstein L; Banai-Eran H; Yanai H; Snir Y; Pauker MH; Friedenberg A; Levy-Barda A; Segal A; Broitman Y; Maoz E; Ovadia B; Golan MA; Shachar E; Ben-Horin S; Perets TT; Ben Zvi H; Eliakim R; Barkan R; Goren S; Navon M; Krugliak N; Werbner M; Alter J; Dessau M; Gal-Tanamy M; Freund NT; Cohen D; Dotan I;
    Gastroenterology; 2022 Feb; 162(2):454-467. PubMed ID: 34717923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan.
    Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
    Respir Investig; 2021 Sep; 59(5):635-642. PubMed ID: 34210623
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
    Doherty J; Fennessy S; Stack R; O' Morain N; Cullen G; Ryan EJ; De Gascun C; Doherty GA
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1110-1123. PubMed ID: 34472643
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis.
    Sung KY; Chang TE; Wang YP; Lin CC; Chang CY; Hou MC; Lu CL
    J Chin Med Assoc; 2022 Apr; 85(4):421-430. PubMed ID: 34974509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patients with inflammatory bowel disease are more hesitant about Coronavirus disease 2019 vaccination.
    Kwon HJ; Panagos K; Alizadeh M; Bell M; Bourmaf M; Zisman E; Paul P; Sibel L; Wong U
    Front Med (Lausanne); 2022; 9():1005121. PubMed ID: 36457565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
    Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD
    Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain.
    Sánchez-Saez F; Peiró S; Cuenca L; Vanaclocha H; Limón R; Salas D; Burgos JS; Sánchez-Payá J; Meneu R; Díez J; García-Sempere A; Navarro IH; Rodríguez-Bernal C; Sanfélix-Gimeno G; Navarro D;
    Vaccine; 2022 Sep; 40(41):5942-5949. PubMed ID: 36068110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post COVID-19 vaccination side effects and associated factors among vaccinated health care providers in Oromia region, Ethiopia in 2021.
    Segni MT; Demissie HF; Adem MK; Geleto AK; Kelkile MW; Sori BK; Heyi ML; Iticha DG; Bejiga GS; Guddisa AB; Sima YA; Amente LT; Bayisa DA; Hurisa MB; Jiru TK
    PLoS One; 2022; 17(12):e0278334. PubMed ID: 36480564
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
    Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
    Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease.
    Bronsky J; Copova I; Durilova M; Kazeka D; Kubat M; Lerchova T; Vlckova E; Mitrova K; Rataj M; Klocperk A; Sediva A; Hradsky O
    J Pediatr Gastroenterol Nutr; 2023 Feb; 76(2):e36-e44. PubMed ID: 36705698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.